

## ASX Announcement

02 January 2024

---

### **Percheron Therapeutics Limited – Name Registered with ASIC**

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY], a biotechnology company focused on the development of novel therapies for rare diseases, is pleased to announce that its change of name to Percheron Therapeutics Limited has been registered with the Australian Securities and Investments Commission (ASIC).

The company has now submitted the change of name to the Australian Securities Exchange (ASX). It is anticipated that, once processed, the company's securities will be listed as 'Percheron Therapeutics Limited' and the company's ticker on ASX will become 'PER'. This process is anticipated to be complete within the next 1 – 2 weeks.

Shareholders are not required to take any action. The change of name and ticker will be processed automatically.

The change of name was approved by shareholders at the company's Annual General Meeting on 15 November 2023<sup>1</sup>.

~ ENDS ~

*This announcement has been authorised for release by the Board.*

**About Antisense Therapeutics Limited** [ASX: ANP | US OTC: ATHJY | FSE: AWY] is a publicly listed biotechnology company developing and commercializing antisense pharmaceuticals for rare diseases with significant unmet medical need. The company's lead program is ATL1102, an antisense inhibitor of the CD49d receptor, which is currently the subject of an ongoing international Phase IIb trial for non-ambulant subjects with Duchenne Muscular Dystrophy. The drug previously reported highly promising results from an exploratory Phase II trial in non-ambulant subjects with DMD.

For more information, please contact [info@antisense.com.au](mailto:info@antisense.com.au)

---

<sup>1</sup> <https://www.antisense.com.au/wp-content/uploads/2023/11/231115-Results-of-Annual-General-Meeting.pdf>